Viela Bio

Autoimmune and severe inflammation


HBM contact: Dr Ivo Staijen

Company status: public

 A clinical-stage biotech pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease. Viela’s lead asset is inebilizumab, a breakthrough treatment for Neuromyelitis optica syndrome spectrum disorder patients.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171